A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

@article{Townsend2021AHT,
  title={A haemagglutination test for rapid detection of antibodies to SARS-CoV-2},
  author={Alain R. Townsend and Pramila Rijal and Julie Xiao and Tiong Kit Tan and Kuan-Ying A. Huang and Lisa Schimanski and Jiandong Huo and Nimesh Gupta and Rolle Rahikainen and Philippa C. Matthews and Derrick W. Crook and Sarah J. Hoosdally and Susanna J . Dunachie and Eleanor J Barnes and Teresa L. Street and Christopher P. Conlon and John Frater and Carolina V Arancibia-C{\'a}rcamo and Justine K. Rudkin and Nicole E. Stoesser and Fredrik Karpe and Matt J. Neville and Rutger J Ploeg and Marta S. Oliveira and David J. Roberts and Abigail Lamikanra and Hoi Pat Tsang and Abbie Bown and Richard Vipond and Alexander J. Mentzer and Julian C. Knight and Andrew J Kwok and Gavin R. Screaton and Juthathip Mongkolsapaya and Wanwisa Dejnirattisai and Piyada Supasa and Paul Klenerman and Christina Dold and John Kenneth Baillie and Shona C Moore and Peter J. M. Openshaw and Malcolm Gracie Semple and Lance C.W. Turtle and Mark Andrew Ainsworth and Alison Allcock and Sally A Beer and Sagida Bibi and Donal T. Skelly and Lizzie Stafford and Katie Jeffrey and Denise O’Donnell and Elizabeth A. Clutterbuck and Alexis Espinosa and Maria Mendoza and Dominique Georgiou and Teresa Lockett and Jose L. Martinez and Elena Perez and Veronica Gallardo Sanchez and Giuseppe Scozzafava and Alberto Sobrinodiaz and Hannah Thraves and Etienne Joly},
  journal={Nature Communications},
  year={2021},
  volume={12}
}
Serological detection of antibodies to SARS-CoV-2 is essential for establishing rates of seroconversion in populations, and for seeking evidence for a level of antibody that may be protective against COVID-19 disease. Several high-performance commercial tests have been described, but these require centralised laboratory facilities that are comparatively expensive, and therefore not available universally. Red cell agglutination tests do not require special equipment, are read by eye, have short… 
A hemagglutination-based, semi-quantitative test for point-of-care determination of SARS-CoV-2 antibody levels
TLDR
A novel rapid, point-of-care RBC agglutination test for the detection of SARS-CoV-2 antibodies that can yield semi-quantitative information on neutralizing antibody titer in patients is developed and may find use in determination of serostatus prior to vaccination, post- vaccination surveillance and travel screening.
A rapid and affordable point of care test for antibodies against SARS-CoV-2 based on hemagglutination and artificial intelligence interpretation
TLDR
Preliminary data support the interpretation that this hemagglutination-based AB test format, which the authors refer to as ‘NanoSpot.ai’, is suitable for POC testing, can be manufactured at very low costs and, based on its generic mode of action, can likely be adapted to a variety of other pathogens.
A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern
TLDR
Overall, HAT provides a surrogate marker for neutralising antibodies, which can be used as a simple inexpensive, rapid test for large-scale evaluation of potentially decreasing vaccine effectiveness.
A simple, sensitive and quantitative FACS-based test for SARS-CoV-2 serology in humans and animals
TLDR
This paper describes an optimized and very simple FACS assay based on staining a mix of two Jurkat cell lines, expressing either high levels of the S protein or the mCherry fluorescent protein, which has a much broader dynamic range than a commercial ELISA test and performs at least as well in terms of sensitivity and specificity.
AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2
TLDR
These findings show that the AstraZeneca COVID-19 vaccine is an effective booster for waning cross-variant antibody immunity after initial priming with SARS-CoV-2 infection and needs to be taken into consideration when formulating vaccination policies in sub-Saharan Africa.
Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay
TLDR
This study evaluated the humoral immune response of BNT162b2 and ChAdOx1 nCoV-19 vaccines using sCOVG and CoV-2 IgG II and compared the quantitative values with the results of the GenScript surrogate virus neutralization test (cPASS; GenScript, USA Inc., NJ, USA).
Modified Hemagglutination Tests for COVID-19 Serology in Resource-Poor Settings: Ready for Prime-Time?
TLDR
Evidence supporting the utility of SARS-CoV-2 Spike kodecytes for clinical diagnostic purposes and serosurveys in resource-poor settings is reviewed.
A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody
  • D. Scheim
  • Biology
    International journal of molecular sciences
  • 2022
TLDR
The arrangement and chemical composition of the glycans at the 22 N-glycosylation sites of SARS-CoV-2 spike protein and those at the sialoglycoprotein coating of RBCs allow exploration of specifics as to how virally induced RBC clumping may form.
Mutational profile confers increased stability of SARS-CoV-2 spike protein in Brazilian isolates.
TLDR
The most predominant mutations in the S protein of Brazilian isolates are analyzed and prediction effects of these amino acid substitutions on the structure dynamics of the spike protein indicated a positive ΔΔG values and negativeΔSVib in most cases which is associated to structural stabilization and flexibility reduction of the Sprotein.
Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
TLDR
Antibody responses declined in all age groups, especially in those ≥60 years, while T cell responses persisted, and the effect of waning of immunity on hospitalization and severe disease should be assessed by long term efficacy studies.
...
1
2
...

References

SHOWING 1-10 OF 26 REFERENCES
A serological assay to detect SARS-CoV-2 seroconversion in humans
TLDR
A serological enzyme-linked immunosorbent assay for the screening and identification of human SARS-CoV-2 seroconverters and can be adjusted to detect different antibody types in serum and plasma.
Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel
TLDR
ELISA can be calibrated to be specific for detecting and quantifying SARS-CoV-2 IgM and IgG and is highly sensitive for IgG from 10 days following first symptoms, however, currently available commercial LFIA devices do not perform sufficiently well for individual patient applications.
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
TLDR
Most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity, and rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
TLDR
A blocking assay based on the recombinant receptor-binding domain of SARS-CoV-2 spike protein and human angiotensin-converting enzyme 2 receptor provides an alternative to conventional antibody neutralization assays requiring live virus.
Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants
TLDR
It is shown here that anti-SARS-CoV antibodies do not convert the abortive infection of primary human macrophages by SARS- coV into a productive one.
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
TLDR
Several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which was identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS- coV) in 2003, and one antibody (named S309) potently neutralization, which may limit the emergence of neutralization-escape mutants.
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
TLDR
EY6A, a neutralizing antibody isolated from a patient convalescing from COVID-19, binds the receptor binding domain of the SARS-CoV-2 spike glycoprotein with high affinity, at a location away from the binding site for the ACE2 receptor, similar to the one recognized by CR3022.
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
TLDR
It is shown that a recombinant vaccine that comprises residues 319–545 of the RBD of the spike protein induces a potent functional antibody response in immunized mice, rabbits and non-human primates as early as 7 or 14 days after the injection of a single vaccine dose.
...
1
2
3
...